analogues are then synthesised, and 2-3 lead molecules are tested in vitro for their activity not only at the primary target of therapeutic interest but also for their secondary effects (safety pharmacology) at other sites, using a panel of pathways known at that time.
Of course, the activity at a single pathway may lead to multiple, often related, indications that share the pathway targeted by the drug.
β-Blockers, indicated for a variety of cardiovascular indications, illustrate this well. Occasionally, it also happens that the molecule under investigation is unexpectedly more active at a target other than originally envisaged, leading the sponsor to pursue a completely different indication. Well-known examples of such drugs are terfenadine and sildenafil, although there are many others. Terfenadine originated from a programme that was aimed at searching for a new neuroleptic agent but its more potent activity on histamine H 1 -receptor led to its development as the first and highly successful nonsedating H 1 -antihistamine.
Similarly, sildenafil was being investigated for its antianginal activity but unanticipated "side effects" during its clinical trials resulted in its development as the first agent ever to treat erectile dysfunction in man.
With revolutionary advances in pharmacology, genomics and medicinal chemistry, a large number of novel molecular pharmacological targets have been, and continue to be, identified. This has led to the development and marketing of many highly targeted and more effective therapeutic agents. Nowhere has this revolution had a greater impact than in oncology. The development of highly targeted small molecules such as protein kinase inhibitors, notably the tyrosine kinase inhibitors (TKIs) and monoclonal antibodies has greatly improved the therapy of a whole range of cancers. For example, the TKI imatinib, following its first approval in 2001, has dramatically improved outcomes in chronic myeloid leukaemia. Imatinib now has no less than seven other distinct indications. Since 2001, 30 other TKIs have been developed, approved and marketed for the treatment of a variety of cancers that were previously treatable only with highly toxic agents. The development of immune checkpoint inhibitors and second-and third-generation TKIs to overcome the resistance to first-generation TKIs further illustrates the importance of identifying novel pathways. However, these extraordinary successes, especially of TKIs, have had a price; namely their unanticipated, and often serious, side effects [2] [3] [4] [5] [6] as well as their cost which is independent of their clinical benefits. 7, 8 The impact of discovery of new pharmacological targets has also extended to some old drugs approved for use in their original indication(s).
This is based on the premise that they were previously tested for their activity only at the then known limited number of pathways, but they could also have activity at the more recently identified novel targets.
In essence, these old drugs are demanding, and deserve, a piece of the action of the revolution in the new arenas of genomics and molecular pharmacology. 9, 10 The story of the current highly effective use of aspirin, widely used since 1897 as an analgesic and an antipyretic agent, in cardiovascular therapeutics following the discovery of cyclo-oxygenase system requires no repetition. Among many others, another example of an old drug with potentially novel application is bepridil, a coronary vasodilator and an antiarrhythmic agent available since the early 1960s. It is a calcium channel antagonist, and studies over the last few years have implicated a role for calcium signalling in Ebola viral entry and, following promising results in early nonclinical in vitro studies, bepridil is considered to be a potential therapeutic agent against the virus. area benefitting most from repurposing of old drugs is oncology. 15 The US National Institutes of Health National Centre for Advancing Compared to the newer agents, not only are these old drugs relatively better tolerated but their safety profile is also well established.
As these drugs are old and off-patent, one of their principal advantages is their cost-effectiveness when used either singly or in combination with other agents.
| ME THODS
Our literature search involved various steps. First, in order to identify drugs with a wide range of clinical and regulatory safety perspectives, we undertook a PubMed search using the terms "repurposing" or "reprofiling" and "cancer". We selected metformin, valproate and astemizole since metformin enjoys wide unfettered use, valproate is under close regulatory scrutiny while astemizole has long been withdrawn from the market. Having identified the three drugs of interest to us, we carried out a further search using the drug name with the term "cancer" to collate nonclinical evidence.
We followed up the above literature search with a further search using the drug name with a variety of terms including "cancer", "repurposing", "reprofiling", "repositioning" and/or "clinical." This allowed us to gather key retrospective clinical studies. Representative retrospective studies were selected for review and inclusion in this review. Finally, we repeated the search adding the term "prospective" or "randomised". We reviewed and included key representative studies following this search.
| RE SULTS

| Metformin
| Use in type 2 diabetes
Biguanides such as buformin, metformin and phenformin have a proven record in the control of blood sugar in Type 2 diabetes mellitus. Buformin and phenformin were the first agents to be approved for use since they were more potent than metformin. However, both
were withdrawn from the market in the late 1970s because of their high propensity to induce lactic acidosis, often with fatal outcome, in patients with renal or hepatic dysfunction. Phenformin-induced lactic acidosis may also occur in patients with its genetically determined impaired metabolic elimination by CYP2D6. 17, 18 Metformin (N, N-dimethyl-biguanide) was discovered in 1922,
and it was first introduced as an oral hypoglycaemic agent in the UK and France in 1957 and much later in the United States in 1995.
The main mechanisms of its antihyperglycaemic effect are inhibition of hepatic glucose production and reduction of insulin resistance. 19 Clinical studies have shown that unlike sulphonylureas and insulin, metformin is unique in having antihyperglycaemic activity without causing overt hypoglycaemia or weight gain. It is also effective in cases of insulin resistance. It is excreted predominantly unchanged in the urine and has a much lower potential for lactic acidosis (at therapeutic doses, <three cases per 100.000 pa-
tient-years). Metformin is on World Health Organisation's List of
Essential Medicines (the most effective and safe medicines needed in a health system) and is now the most widely used oral medication for Type 2 diabetes. Widely available as a generic medication, it is also very cheap.
Initially, metformin-containing medicines were contraindicated in patients with moderate reduction of kidney function. However, following a detailed review of its use and safety, the European Medicines Agency (EMA), in October 2016, revised the previous recommendations by concluding that metformin-containing medicines can be used in patients even with moderately reduced kidney function (glomerular filtration rate (GFR) between 30 and 59 mL/min) while contraindicating its use in patients with GFR < 30 mL/min. It also recommended that GFR should be assessed before initiation of treatment and at least annually thereafter.
| Potential use in oncology
The overall evidence supporting the potential beneficial effects of metformin in oncology has been reviewed previously 20 and is summarized briefly below. The reader is also referred to other reviews for further details of its potential anticancer properties. [21] [22] [23] [24] [25] [26] Metformin has been shown to inhibit proliferation of cancer cells in a number of in vitro studies. For example, glioblastoma is the most common and aggressive type of primary brain cancer, and the current standard therapy consists of maximal surgical resection within safe limits, followed by radiation therapy and chemotherapy with temozolomide. In the most recently published nonclinical study, the combination of metformin and temozolomide was superior to monotherapy using metformin or temozolomide in terms of glioblastoma cell viability in vitro and survival in vivo in the glioblastoma orthotopic mice model. 36 Metformin has also been reported to reduce temozolomide resistance in glioblastoma cell lines. 37 Paradoxically, a number of TKIs and mTOR inhibitors used in oncology are associated with drug-induced hyperglycaemia. 20 Given their structural and pharmacological similarities, it is not altogether surprising that phenformin, through regulation of IGF-1/ IGF-1R-mediated pathway, has also been shown to have potential anticancer activity. 38 Nonclinical findings suggest that combining phenformin with a BRAF inhibitor may be a more effective treatment than a single-agent BRAF inhibitor for treating patients with melanoma, harbouring BRAF mutations. 39 In the most recent study using three ovarian cancer cell lines, 40 phenformin significantly inhibited cellular proliferation, induced cell cycle G1 arrest and apoptosis, caused cellular stress, inhibited adhesion and invasion, and caused activation of AMPK and inhibition of the mTOR pathway. Phenformin also exerted antiproliferative effects in seven primary cell cultures of human ovarian cancer. In this study, phenformin also inhibited tumour growth in an orthotopic mouse model of serous ovarian cancer. 40 Clinically, Type 2 diabetes mellitus has been linked with increased risk of cancers such as those of colon/rectum, breast, bladder and pancreas, 41, 42 and treatment of diabetes with metformin is reported to reduce the risk of cancers. 43, 44 Diabetes is also a prognostic factor that influences clinical outcomes in cancer. [45] [46] [47] [48] However, a study by Häggström et al 49 provided no support to the hypothesis that metformin protects against prostate cancer.
The number of clinical studies examining the effect of metformin on disease outcomes in various cancers is increasing rapidly, a vast majority of these being observational retrospective studies. These population-based studies strongly suggest that treatment with metformin is associated with a dose-dependent reduction in cancer mortality. ated. 63 In a cohort of patients with diabetes receiving systemic chemotherapy for invasive breast cancer, the use of metformin was not associated with improved outcomes. 64 Similarly, another retrospective cohort study has also reported that use of metformin during docetaxel chemotherapy did not significantly improve prostate cancer-specific or OS survival in diabetic patients with metastatic castration-resistant prostate cancer. 65 However, in one retrospective study of 543 patients with rectal cancer, metformin was associated with higher rates of tumour response to radiotherapy, especially in patients with diabetes. 66 At present, there are only a few prospective randomised controlled trials aimed at validating the findings from observational studies, and the few that are available have failed to confirm the anticipated benefits in NSCLC, 67 pancreatic cancer 68, 69 and breast cancer. 70 For example, Kordes et al 68 designed to detect acute toxicities in this study, has determined that metformin dose is defined at 1500 mg/day to be combined with erlotinib 150 mg. 74 These investigators also comment that the usual antidiabetic dose of metformin may not reflect the antitumour efficacy of the drug and that metformin doses higher than 1500 may be too toxic for nondiabetic patients when combined with erlotinib.
| Summary of evidence of anticancer properties of metformin
There is a sound pharmacological and molecular basis to suggest that metformin has anticancer properties. This is supported experimentally by data from in vitro and nonclinical in vivo studies. Clinically, some retrospective studies have also reported that metformin (a) reduces the risk of cancers and (b) improves survival in cancer patients. However, other retrospective studies and the few prospective studies that have been reported have failed to confirm improved survival in metformin users. Clearly, the current evidence base is inconsistent. This may be explained in part by the wide range of cancer types studied without due regard to biomarkers of their chemosensitivity and in part by potential failure to achieve effective drug concentrations in the neoplastic tissue. Since the effect of metformin becomes evident only with increasing duration and its cumulative dose, [75] [76] [77] [78] it is important that prospective randomised controlled trials are of appropriate duration. Kordes et al 68 have suggested that future research should include studies of more potent biguanides and should focus on patients with hyperinsulinaemia and patients with tumours showing markers of sensitivity to energetic stress, such as loss of function of AMP kinase which is a key regulator of cellular energy homoeostasis.
| Valproate
| Use in epilepsy
Valproate or valproic acid (VPA) is n-dipropylacetic acid. This shortchain fatty acid was first synthesised in the early 1880s, and it was originally used as a solvent for other compounds. Its anticonvulsant properties were discovered by chance in 1962 by Pierre Eymard while using it as a vehicle for a number of other compounds that were being screened for their anticonvulsant activity. 79 It was in- in 1972, valid initially for 1 year, was conditional and subject to special "monitored release" to corroborate its alleged lack of teratogenic potential. Since VPA was marketed in the above countries without any clinical evidence of teratogenic effects and the initial monitored release in the UK showed it to be devoid of teratogenicity, the UK authority granted a full licence in 1974 for wider marketing of VPA subject to its use in women of child-bearing age being restricted to severe cases or those resistant to other treatment and a warning on its teratogenic potential being included in the product literature.
In 1982, however, neural tube defects were reported in nine babies born in the Rhône-Alpes region of France to women given VPA. 80 Since that early report, the teratogenic and adverse developmental and neurocognitive effects of VPA, compared to other anticonvulsants, have attracted frequent attention from all stakeholders including the regulatory authorities and patient groups. Although VPA is teratogenic, it is also highly effective, often being the only drug effective in many patients, and it continues to remain on the market. 
| Potential use in oncology
Epigenetic regulation refers to alterations in gene function due to Additionally, chidamide is also approved in China for peripheral T-cell lymphoma. A recent Phase II study in 13 patients with a variety of advanced radioiodine negative thyroid cancers also reported that VPA, administered orally and at doses adjusted to maintain serum trough levels between 50 and 100 mg/L for 10 weeks, did not increase radio-iodine uptake and did not have anticancer activity in patients with advanced, radio-iodinenegative thyroid cancer of follicular cell origin. 104 The potential beneficial effects of VPA in patients with glioblastoma were reported well before it was identified as an HDAC inhibitor. 105 The pharmacokinetic properties of VPA are particularly suited to its potentially beneficial use in glioblastoma. Epilepsy was an independent prognostic factor, and this prognostic effect could not be solely explained by early diagnosis; the use of VPA was not associated with improved survival. is the V-CHANCE study which is a Phase II clinical trial evaluating the concomitant standard administration of cisplatin and cetuximab in combination with oral VPA given daily from day-14 (with a titration strategy to achieve target concentrations) in patients with recurrent/metastatic squamous cell carcinoma of the head and neck who have never been treated with first-line chemotherapy. 
The evidence linking histamine per se to cancer is complex, and a detailed consideration is beyond the scope of this review. It is known that immune factors are involved in the development of glioblastoma, and there is a well-established inverse association between history of allergies and risk of glioma. [142] [143] [144] Asthma and eczema are also significant factors that protect against glioma. 145, 146 Previous studies have demonstrated that IgE levels are also lower in glioma patients than in controls, 147, 148 suggesting that atopic allergy may be related to a mechanism that inhibits or prevents glioma. There are inverse associations (a) between TGFβ2 and glioblastoma and (b) between IL4 and sIL4RA and both glioma and glioblastoma. 149 Use of antihistamines reportedly increases the risk of highly anaplastic glioma. One exciting discovery over the last few years is the role of ether-a-go-go (EAG), and the closely related human ether-a-go-go (hERG), potassium channels in carcinogenesis. [159] [160] [161] [162] [163] KCNH1 gene encodes for EAG1 channel whereas hERG is encoded by KCNH2
gene. Inhibition of the hERG channel is the principal mechanism in humans by which drugs induce QT interval prolongation and torsade de pointes. 164 For an historical account and further details of the highly complex mechanisms involved in the role of EAG/hERG in carcinogenesis, the reader is referred to other reviews. 160, 161, [165] [166] [167] [168] [169] [170] Ether-a-go-go and hERG are expressed in various cancers and have been implicated in cell cycle progression and proliferation of cancer cells. Using astemizole (a nonspecific hERG blocker) and E-4031 (a specific hERG blocker), it has been demonstrated that the functions of hEAG and hERG channels can be separated pharmacologically. 171 Following the initial description of hEAG/hERG channel in humans, 172 Bianchi et al 173 cancer at mRNA (sensitivity = 67%; n = 18) and protein levels (sensitivity = 82%; n = 18), whereas only 18% (n = 11) of noncancerous endometrial samples exhibited hERG mRNA or protein.
Inhibition of EAG1/hERG channels has been shown, both in vitro and in vivo, to reduce cell proliferation, thus identifying inhibitors of these channels as putative inhibitors of tumour progression. 160 E-4031 is a potent inhibitor of hERG channel and has been shown to reduce proliferation of three leukaemia cell lines. 177 Similarly, cisapride, another potent hERG inhibitor, inhibited the growth of gastric cancer cells by altering distribution of cell cycle and inducing apoptosis. 182 hERG protein has been shown to be exclusively expressed in gastric cancer cells, and its expression was associated with tumour differentiation, metastatic staging and lymph node involvement. 183 In the most recent study, patients who received at least one hERG blocker had a better survival rate compared with those who did not (P = 0.0015). 184 Subgroup analysis in this study showed that glioblastoma patients with high hERG expression who received hERG blockers had improved survival (P = 0.0458) whereas there was no difference in survival for low hERG-expressing glioblastoma patients who received hERG blockers (P = 0.4136). Sparfloxacin is a fluoroquinolone antibiotic that was withdrawn from the market because, apart from its phototoxicity, it induced QT interval prolongation and torsade de pointes by inhibiting the hERG channel. and showed synergistic effect with 5-fluorouracil in vivo. 191 Since sparfloxacin is not known to be active at histamine receptors, it seems reasonable to conclude that its anticancer property is related to its hERG channel blocking activity.
A number of TKIs widely used in oncology are known to inhibit the hERG channel, prolong the QT interval and rarely, also induce torsade de pointes, 3, 192 further raising the probability of a link be- suggested that drug testing requirements to identify acquired long QT syndrome risk must change and specific studies of PI3K-dependent effects that develop over time should be included in drug safety testing. As stated above with regard to metformin, IGF-1R and its ligands, IGF-1 and IGF-2, are also upregulated in a variety of human cancers. 32 Stimulation of the IGF-1R and IR activates the PI3K/AKT/ mTOR pathway. 34 IGF-1 increases both the activity and the expression of hEAG channels through an AKT-dependent pathway, 195 and restoration of depressed hERG channel function is proposed as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits. 196 Although some HDAC inhibitors have also been reported to inhibit hERG channel through complex transcriptional changes of genes required for ion channel trafficking, 197 there is no evidence that VPA (discussed above)
prolongs the QT interval [198] [199] [200] and therefore, by inference, does not inhibit the hERG channel. increased apoptosis approximately four times in comparison to the effect of either drug alone. These results led them to suggest that the astemizole-gefitinib combination may be a novel and promising therapy for lung cancer patients. Available evidence strongly suggests that vitamin D is also an anticancer agent. 205 In a study that explored the combined anticancer effect of calcitriol and astemizole in vivo using mice xenografted with the human breast cancer cell line (T-47D) and a primary breast cancer-derived cell culture (MBCDF), the concomitant administration of calcitriol and astemizole inhibited tumour growth more efficiently than either drug alone. 206, 207 Garcia-Becerra et al 208 have shown that calcitriol suppressed EAG1 expression through a vitamin D receptor-dependent mechanism.
This effect was accompanied by inhibition of cell proliferation, which was potentiated by astemizole, a nonspecific EAG1 inhibitor.
The proarrhythmic effect of a QT-prolonging hERG blocker is also modulated by other ion channel effects, and therefore, hERG blockade for anticancer activity does not need to equate with QT-related proarrhythmias. A number of compounds, commonly used in the clinical setting, effectively block hERG channels without inducing proarrhythmias.
One good example is sertindole, an antipsychotic agent. However, a study, aimed at evaluating the proarrhythmic doses of astemizole using the atrioventricular block dogs and clarifying the cardiac safety profile of its anticancer doses used in nonclinical studies, has reported that the proarrhythmic dose of astemizole would be lower than its anticancer dose, thus limiting its repurposing as an anticancer drug. is inhibited by astemizole and loratadine (as well as cisapride). 219 Thus, this additional mechanism implicating CYP2J2 may provide at least a partial explanation of the effects of astemizole and loratadine on mortality of patients diagnosed with nonlocalized cancer. 
| Summary of evidence of anticancer properties of astemizole
In vitro and nonclinical in vivo studies suggest that astemizole has two distinct potential anticancer properties-inhibition of the hERG channel and cytochrome CYP2J2, both of which are upregulated/ overexpressed in various cancers. We could find only one retrospective study that suggested that astemizole was significantly associated with reduced mortality in patients with any nonlocalized cancer. Available nonclinical studies suggest that astemizole may act synergistically when combined with other agents such as gefitinib but no clinical study has investigated this hypothesis.
| CHALLENG E S AND OVERCOMING O B S TACLE S
Langedijk et al 220 analysed in a quantitative and qualitative manner how terms related to repurposing are used and defined in the literature and could not identify any common definition. Nevertheless, they identified four common features, namely concept, action, use and product. Therefore, we suggest that the term "repurposing", and the related terms "repositioning" and "reprofiling", should be reserved only when the following criteria are met:
1. Old drugs either discarded or long out of patent are being considered.
2.
The investigations are based on recently discovered mechanism(s) of action. It seems that the present approach to investigating the efficacy of old drugs in oncology indications is less than optimal. Principal weaknesses are heterogeneity of tumour types studied without due regard to oncogenic molecular signatures, pharmacological mechanism(s) responsible or tumour gradation and trials of short duration with poorly characterized effective dose schedules and lack of statistical power. Our literature search suggests these deficiencies to be more widely applicable to a number of old drugs.
Ethnicity of the study population should not be overlooked.
Regulatory authorities increasingly require subgroup analysis of data by ethnicity. 221 The inverse association between glioma and atopic conditions reportedly varies with ethnicity, there being no association in the black population. 222 Heath et al 223 214 and its peak plasma concentration after an oral dose of 120 mg is approximately 3 μmol/L. These data must no doubt raise question marks on the risk/benefit of prenylamine were it to be tested for use in oncology.
With the evidence available at present, it is difficult to recommend the use of any of the three drugs reviewed herein for use in oncology. More robust evidence from prospective studies is required.
It is evident that despite strong support from retrospective studies, prospective studies have often revealed lack of any benefit. The recently reported LUNGSTAR study illustrates the point. Statins, widely used in cardiovascular prevention strategies, are reported to have tissue-specific anticancer properties, 228 although there is some evidence to the contrary. 229 LUNGSTAR was one of the largest prospective studies investigating the benefits of adding pravastatin at a daily dose of 40 mg to standard chemotherapy in patients with small cell lung cancer. 230 In this study, pravastatin performed no better than
placebo. An important question that arises is whether effective antioncogenic concentrations of pravastatin had been achieved during the study. Given that the effect and the risk/benefit of an old drug depend on its pharmacokinetics, on target and off-target potencies and tissue concentrations, caution must be exercised in dismissing other members of its class if one particular member is found to be ineffective. For example, Gyawali et al 71 have argued for investigating simvastatin (although pravastatin failed) in improving the outcomes in patients with small cell lung cancer treated with chemotherapy. 230, 231 These two statins differ markedly in their hydrophobicity; simvastatin being hydrophobic and pravastatin being hydrophilic.
In an analysis of 15 new drug applications for oncology indications that were rejected by the FDA, the two main reasons for rejection were lack of efficacy of the study drug (n = 10; 67%) and clinical trial design flaws (n = 5; 33%). None of the applications was rejected solely on the basis of safety. 232 With this in mind and the data reviewed in this review, we would like to propose the following scheme when it comes to repurposing and investigating an old drug prospectively for its use in oncology:
In vitro and nonclinical in vivo studies to investigate tumour-specific potential efficacy and define effective concentrations.
Investigation of the drug as a radiosensitizer either alone or in combination with other approved agents
Investigating the efficacy of the drug compared to placebo in combination with approved agents in adequately designed and powered studies If the results of combination studies are encouraging, investigating the efficacy of the drug compared to the approved agent in adequately designed and powered studies.
Investigating whether the drug can reverse resistance to other chemotherapeutic agents.
Characterizing the effect of the drug on reducing the dose or minimizing toxicity of an approved agent without mitigating efficacy.
Confirming that the safety profile of the drug (adverse reactions and interactions) remains acceptable. In this context, it is worth bearing in mind the possibility of an orphan drug status with all the associated benefits to the sponsor.
| WHAT IS NE W AND CON CLUS I ON S
Orphan drug status should be sought as soon as there is sufficient preliminary evidence but before embarking on pivotal clinical trials.
The benefits of orphan drug status include protocol assistance at no cost and market exclusivity. We recommend that if an old drug is found to have a potential for use in an oncology indication, the sponsor should seek a formal marketing authorization rather than encourage its off-label use during routine clinical practice.
Without doubt, thalidomide must represent the greatest success story in repurposing. It was originally developed and marketed outside the United States as a hypnotic agent. It was rejected by the FDA and soon removed from other markets in the early 1960s because of its highly teratogenic effects. Although its mechanism is not fully understood, it is known to possess immunomodulatory, anti-inflammatory and antiangiogenic properties. Some 40 years later, it was investigated and approved (albeit under a tightly-controlled special restricted distribution programme to mitigate any risks of teratogenic outcomes), for use in leprosy and multiple myeloma (both being orphan indications).
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